Based on these fundamental studies, several preclinical trials of these combination therapies have been conducted, including rituximab for B cell non-Hodgkin’s lymphoma (52) and trastuzumab for HER2-overexpressing cancer (53,54). This evidence concerns the gene ERBB2 and B-cell non-Hodgkin lymphoma.